X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6645) 6645
Publication (474) 474
Book Review (402) 402
Conference Proceeding (17) 17
Book Chapter (16) 16
Dissertation (6) 6
Magazine Article (2) 2
Paper (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5618) 5618
humans (3502) 3502
male (2613) 2613
anilides - pharmacology (2489) 2489
animals (2341) 2341
anilides - therapeutic use (1445) 1445
female (1167) 1167
anilides (1030) 1030
middle aged (904) 904
rats (873) 873
mice (856) 856
aged (826) 826
prostatic neoplasms - drug therapy (683) 683
anilides - administration & dosage (680) 680
pharmacology & pharmacy (638) 638
oncology (617) 617
anilides - chemistry (583) 583
anilides - adverse effects (569) 569
abridged index medicus (542) 542
adult (535) 535
cell line, tumor (515) 515
nitriles (510) 510
prostate cancer (508) 508
tosyl compounds (508) 508
cancer (463) 463
anilides - metabolism (436) 436
biochemistry & molecular biology (433) 433
dose-response relationship, drug (422) 422
antineoplastic agents - therapeutic use (417) 417
time factors (410) 410
chemistry, organic (408) 408
pyridines - therapeutic use (396) 396
kinetics (393) 393
androgen antagonists - therapeutic use (385) 385
prostatic neoplasms - pathology (371) 371
anilides - chemical synthesis (368) 368
urology & nephrology (353) 353
structure-activity relationship (351) 351
research (325) 325
treatment outcome (319) 319
expression (318) 318
aged, 80 and over (313) 313
chemistry (307) 307
ppar gamma - antagonists & inhibitors (300) 300
analysis (298) 298
antineoplastic agents - pharmacology (297) 297
androgen antagonists - pharmacology (296) 296
encainide (294) 294
ppar gamma - metabolism (294) 294
article (284) 284
care and treatment (279) 279
signal transduction - drug effects (279) 279
activation (274) 274
chemistry, medicinal (274) 274
pyridines - pharmacology (271) 271
chemistry, multidisciplinary (270) 270
cells, cultured (263) 263
bicalutamide (258) 258
cell proliferation - drug effects (255) 255
molecular structure (255) 255
receptors, androgen - metabolism (243) 243
nitriles - pharmacology (239) 239
anilides - pharmacokinetics (238) 238
in vitro techniques (233) 233
tosyl compounds - pharmacology (225) 225
cell biology (224) 224
apoptosis (215) 215
prostatic neoplasms - metabolism (215) 215
carcinoma (213) 213
ligands (212) 212
rats, sprague-dawley (211) 211
catalysis (207) 207
therapy (206) 206
hydrogen-ion concentration (205) 205
nitriles - therapeutic use (204) 204
drug therapy, combination (202) 202
endocrinology & metabolism (200) 200
thiazolidinediones - pharmacology (197) 197
chemical phenomena (195) 195
tosyl compounds - therapeutic use (195) 195
anilides - toxicity (193) 193
apoptosis - drug effects (191) 191
disease models, animal (190) 190
dogs (188) 188
signal transduction (187) 187
cells (182) 182
clinical trials as topic (178) 178
carcinoma, basal cell - drug therapy (177) 177
metastasis (175) 175
flutamide - pharmacology (174) 174
skin neoplasms - drug therapy (174) 174
administration, oral (173) 173
cell line (169) 169
prostate-specific antigen - blood (168) 168
stereoisomerism (168) 168
anti-arrhythmia agents - therapeutic use (166) 166
growth (166) 166
derivatives (165) 165
toxicology (164) 164
androgen receptor (163) 163
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6045) 6045
German (212) 212
Japanese (79) 79
Italian (78) 78
Russian (70) 70
French (65) 65
Chinese (33) 33
Spanish (21) 21
Polish (15) 15
Czech (14) 14
Ukrainian (9) 9
Norwegian (5) 5
Portuguese (5) 5
Danish (4) 4
Swedish (4) 4
Dutch (3) 3
Hungarian (3) 3
Slovak (3) 3
Croatian (2) 2
Finnish (2) 2
Hebrew (2) 2
Bulgarian (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Neuropharmacology, ISSN 0028-3908, 03/2013, Volume 66, pp. 158 - 169
Group III metabotropic glutamate (mGlu) receptors are localized in presynaptic terminals within basal ganglia (BG) circuitry that become hyperactive due to... 
Striatum | Basal ganglia | Akinesia | Rat | Lu AF21934 | l-DOPA-induced dyskinesia | Electrophysiology | HIGH-FREQUENCY STIMULATION | NEUROLOGICAL DISEASES | NEUROSCIENCES | RAT MODEL | STRIATAL SYNAPTIC PLASTICITY | MEDIATED MODULATION | SUBTHALAMIC NUCLEUS | UNILATERAL 6-HYDROXYDOPAMINE LESIONS | PHARMACOLOGY & PHARMACY | DEEP BRAIN-STIMULATION | L-DOPA-induced dyskinesia | MOLECULAR-MECHANISMS | Anilides - therapeutic use | Catalepsy - drug therapy | Synaptic Transmission - physiology | Excitatory Amino Acid Agonists - therapeutic use | Receptors, Metabotropic Glutamate - physiology | Male | Aminobutyrates - pharmacology | Anilides - pharmacokinetics | Parkinson Disease - drug therapy | Oxidopamine | Aminobutyrates - therapeutic use | Excitatory Postsynaptic Potentials - drug effects | Dose-Response Relationship, Drug | Excitatory Postsynaptic Potentials - physiology | Haloperidol - antagonists & inhibitors | Allosteric Regulation - physiology | Dyskinesia, Drug-Induced - drug therapy | Catalepsy - chemically induced | Synaptic Transmission - drug effects | Haloperidol - pharmacology | Disease Models, Animal | Allosteric Regulation - drug effects | Aminobutyrates - agonists | Levodopa - pharmacology | Cyclohexanecarboxylic Acids - therapeutic use | Phosphinic Acids - agonists | Levodopa - therapeutic use | Phosphinic Acids - therapeutic use | Rats | Excitatory Amino Acid Agonists - pharmacology | Rats, Sprague-Dawley | Drug Synergism | Animals | Cyclohexanecarboxylic Acids - pharmacology | Levodopa - adverse effects | Phosphinic Acids - pharmacology | Anilides - pharmacology | Excitatory Amino Acid Agonists - pharmacokinetics | Cyclohexanecarboxylic Acids - pharmacokinetics | Receptors, Metabotropic Glutamate - agonists | Receptors, Metabotropic Glutamate - antagonists & inhibitors | Physiological aspects | Phenols | Amino acids | Parkinson's disease | Glutamate | Drug therapy | Index Medicus | 6-Hydroxydopamine | Phosphinic Acids | Excitatory Amino Acid Agonists | Allosteric Regulation | Catalepsy | Haloperidol | Aminobutyrates | Cellular Biology | Synaptic Transmission | Receptors, Metabotropic Glutamate | Parkinson Disease | Anilides | Life Sciences | Excitatory Postsynaptic Potentials | Cyclohexanecarboxylic Acids | Dyskinesia, Drug-Induced | Levodopa
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 23, pp. 2171 - 2179
Journal Article
Science, ISSN 0036-8075, 3/2009, Volume 323, Issue 5921, pp. 1593 - 1597
Journal Article
Journal of Infection, ISSN 0163-4453, 2014, Volume 70, Issue 2, pp. 197 - 205
Summary Objectives To examine the safety and efficacy of ombitasvir and ABT-450 with ritonavir (ABT-450/r) ± ribavirin (RBV) in treatment-naïve, non-cirrhotic... 
Infectious Disease | HCV genotype 2 | HCV genotype 3 | SVR24 | SVR12 | Hepatitis C virus | Sustained virologic response | Interferon-free therapy | SVR | INFECTIOUS DISEASES | ABT-450/R-OMBITASVIR | SOFOSBUVIR | COMBINATION | LEDIPASVIR | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2B | DASABUVIR | CIRRHOSIS | INTERFERON PLUS RIBAVIRIN | EPIDEMIOLOGY | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Macrocyclic Compounds - pharmacology | Ribavirin - administration & dosage | Adult | Female | Hepatitis C, Chronic - epidemiology | Drug Therapy, Combination | Carbamates - pharmacology | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Anilides - pharmacology | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Ribavirin - pharmacology | Genetic aspects | Health aspects | Liver cirrhosis | Ribavirin | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 1, pp. 54 - 63
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992